Non Muscle Invasive Bladder Cancer (NMIBC)– Pipeline Insight, 2020
This report can be delivered to the clients within 72 - 96 Hours
DelveInsight’s, “Non Muscle Invasive Bladder Cancer (NMIBC)– Pipeline Insight, 2020,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Non-Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Non Muscle Invasive Bladder Cancer: Overview
NMIBC is defined as a superficial neoplasia confined to the mucosa, (including Ta which is a noninvasive papillary carcinoma and carcinoma in situ (CIS), which is flat and non-papillary) or lamina propria (T1) based on the American Joint Committee on Cancer (AJCC) staging system, also known as the tumor node metastases (TNM) classification. Ta accounts for most NMIBC (60%), whereas T1 and Tis (CIS) account for 30% and 10%, respectively.
Symptoms
Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:
The following tests may be done to determine bladder cancer:
The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy. Pembrolizumab is approved for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy
Non Muscle Invasive Bladder Cancer Emerging Drugs Chapters
This segment of the Non Muscle Invasive Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non Muscle Invasive Bladder Cancer Emerging Drugs
Further product details are provided in the report……..
Non Muscle Invasive Bladder Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Non Muscle Invasive Bladder Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Non Muscle Invasive Bladder Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non Muscle Invasive Bladder Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non Muscle Invasive Bladder Cancer drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Non Muscle Invasive Bladder Cancer (NMIBC)– Pipeline Insight, 2020,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Non-Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Non Muscle Invasive Bladder Cancer: Overview
NMIBC is defined as a superficial neoplasia confined to the mucosa, (including Ta which is a noninvasive papillary carcinoma and carcinoma in situ (CIS), which is flat and non-papillary) or lamina propria (T1) based on the American Joint Committee on Cancer (AJCC) staging system, also known as the tumor node metastases (TNM) classification. Ta accounts for most NMIBC (60%), whereas T1 and Tis (CIS) account for 30% and 10%, respectively.
Symptoms
Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:
- Hematuria (blood in the urine) - the most common symptom, often without pain
- Frequent and urgent urination
- Pain when urine passes
- Pain in lower abdomen
- Back pain
The following tests may be done to determine bladder cancer:
- Urine cytology: The color and content of the urine will be checked. This test will also look at body cells under a microscope.to test for cancer cells.
- Blood tests: A comprehensive metabolic panel (CMP), which includes kidney and liver function tests
- A. Computerized tomography scan (also known as CT or CAT scans) with a bladder scope 'cystoscopy' are often good enough to diagnose bladder cancer.
- Cystoscopy: A doctor will use a thin tube that has a light and camera at the end of it (cystoscope) to pass through the urethra into the bladder.
The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy. Pembrolizumab is approved for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy
Non Muscle Invasive Bladder Cancer Emerging Drugs Chapters
This segment of the Non Muscle Invasive Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non Muscle Invasive Bladder Cancer Emerging Drugs
- Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals
- UGN-102: UroGen Pharma
Further product details are provided in the report……..
Non Muscle Invasive Bladder Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Non Muscle Invasive Bladder Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Non-Muscle Invasive Bladder Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Non Muscle Invasive Bladder Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non Muscle Invasive Bladder Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non Muscle Invasive Bladder Cancer drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Non Muscle Invasive Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non Muscle Invasive Bladder Cancer.
- In July 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical had signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.
- In April 2020, UroGen Pharma announced positive interim data analysis of UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). These data were featured in a late-breaking abstract published in the April Supplement to The Journal of Urology. The detailed results presentation will be available online via the American Urological Association (AUA) in mid-May 2020.
- Non Muscle Invasive Bladder Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Non Muscle Invasive Bladder Cancer drugs?
- How many Non Muscle Invasive Bladder Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non Muscle Invasive Bladder Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non Muscle Invasive Bladder Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Non Muscle Invasive Bladder Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Viventia Bio
- Viralytics
- Vaxiion Therapeutics
- UroGen Pharma Ltd.
- EMD Serono
- AstraZeneca
- Hoffmann-La Roche
- Theralase Inc
- Telormedix
- Taris Biomedica
- Spectrum Pharmaceuticals
- Incyte Corporation
- Rapamycin Holding
- Pfizer
- NanOlogy
- Merck Sharp & Dohme Corp.
- Lipac Oncology
- Jiangsu Yahong Meditech Co.,Ltd.
- Janssen Research & Development, LLC
- Hoffmann-La Roche
- Handok
- Hamlet Pharma AB
- Halozyme Therapeutics
- Apices Soluciones
- FKD Therapies
- H3 Biomedicine Inc.
- CG Oncology, Inc.
- Bioniche Life Sciences Inc.
- BioCis Pharma
- Asieris Pharmaceutical
- Archivel Farma
- Altor BioScience
- Aadi,
- Vicinium
- Instiladrin
- PF-06801591
- Atezolizumab
- APL 1202
- Imfinzi
- Opdivo
- Apaziquone
- CG0070
- Inodiftagene vixteplasmid
- Balversa
- LiPax (paclitaxel)
- Pemigatinib
- TLD 1433
- ALT-803
- Lenalidomide
- UGN-102
- ABI-009
- ALT-801
- Alpha1H
- NanoDoce
- HS-410
- Avelumab
- BGJ398
- UGN-201
- TAR 200
- E7766
- VAX014
- Cavatak
- UGN-302
- ATX 101
- TL-532
- Bladder Cancer Program
Introduction
Executive Summary
Non Muscle Invasive Bladder Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Non Muscle Invasive Bladder Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Non Muscle Invasive Bladder Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Non Muscle Invasive Bladder Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
UGN-102: UroGen Pharma
Product Description
Research and Development
Product Development Activities
Inodiftagene Vixteplasmid: Anchiano Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TAR 200: TARIS Biomedical
Product Description
Research and Development
Product Development Activities
E7766: H3 Biomedicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
UGN-302: UroGen Pharma
Product Description
Research and Development
Product Development Activities
ATX 101: APIM Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Non Muscle Invasive Bladder Cancer Key Companies
Appendix
Executive Summary
Non Muscle Invasive Bladder Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Non Muscle Invasive Bladder Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Non Muscle Invasive Bladder Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Non Muscle Invasive Bladder Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
UGN-102: UroGen Pharma
Product Description
Research and Development
Product Development Activities
Inodiftagene Vixteplasmid: Anchiano Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TAR 200: TARIS Biomedical
Product Description
Research and Development
Product Development Activities
E7766: H3 Biomedicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
UGN-302: UroGen Pharma
Product Description
Research and Development
Product Development Activities
ATX 101: APIM Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Non Muscle Invasive Bladder Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Non Muscle Invasive Bladder Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Non Muscle Invasive Bladder Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Non Muscle Invasive Bladder Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Non Muscle Invasive Bladder Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products